Eubel Brady & Suttman Asset Management Inc. Sells 200 Shares of Merck & Co., Inc. $MRK

Eubel Brady & Suttman Asset Management Inc. cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,866 shares of the company’s stock after selling 200 shares during the quarter. Eubel Brady & Suttman Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $464,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MRK. Brighton Jones LLC raised its position in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the last quarter. MorganRosel Wealth Management LLC bought a new position in Merck & Co., Inc. in the first quarter valued at about $36,000. Richardson Capital Management LLC bought a new position in Merck & Co., Inc. in the first quarter valued at about $109,000. Beaton Management Co. Inc. raised its position in Merck & Co., Inc. by 6.3% in the first quarter. Beaton Management Co. Inc. now owns 20,287 shares of the company’s stock valued at $1,821,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Barnes Dennig Private Wealth Management LLC bought a new position in Merck & Co., Inc. in the first quarter valued at about $27,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRK has been the subject of several research reports. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Morgan Stanley decreased their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $104.33.

Merck & Co., Inc. Stock Down 1.0%

Shares of NYSE:MRK opened at $87.13 on Wednesday. The business’s 50 day simple moving average is $84.55 and its two-hundred day simple moving average is $81.67. The firm has a market cap of $217.62 billion, a P/E ratio of 13.42, a PEG ratio of 0.97 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $105.11.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. As a group, research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.